Better Buy: Bristol Myers Squibb vs. Gilead Sciences
There are few names more well-known in the biopharmaceutical world than Bristol Myers Squibb (NYSE: BMY) and Gilead Sciences (NASDAQ: GILD). While neither stock was immune to the coronavirus bear market plunge in March, both companies managed to stave off much of the volatility impacting their competitors in the broader market.
Gilead has gained increasing attention in the news of late. In early May, the U.S. Food and Drug Administration (FDA) authorized the emergency use of the company's antiviral medication remdesivir to treat critically ill COVID-19 patients. Gilead is donating millions of doses of the drug globally, as more countries around the world have approved it for severely ill patients. Taiwan is the latest nation to clear the drug to treat COVID-19 patients. Bristol Myers has proffered its research capabilities and over 1,000 different compounds to companies collaborating on prospective COVID-19 solutions as its contribution to battle the pandemic.
Both Bristol Myers Squibb and Gilead Sciences have extremely solid pipelines of existing products and strong core financials. So today's burning question is, which stock is the better buy?
Source Fool.com
